“VOMITING IS A POTENTIAL ADVERSE DRUG REACTION FOR LEVOMILNACIPRAN” (2017) International Journal of Pharmaceutical Sciences and Drug Research, 9(5), pp. 224–227. doi:10.25004/IJPSDR.2017.090504.